Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Cecilia Bahit M, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, Fox KAA, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua K, Hylek E, Toda Kato E, Kuder J, Lopes RD, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242–55. https://doi.org/10.1161/CIRCULATIONAHA.121.056355.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fong KY, Chan YH, Yeo C, Lip GYH, Tan VH. Systematic review and meta-analysis of direct oral anticoagulants versus warfarin in atrial fibrillation with low stroke risk. Am J Cardiol. 2023;204:366–76. https://doi.org/10.1016/j.amjcard.2023.07.108.

Article  CAS  PubMed  Google Scholar 

Bortman LV, Mitchell F, Naveiro S, et al. Direct oral anticoagulants: an updated systematic review of their clinical pharmacology and clinical effectiveness and safety in patients with nonvalvular atrial fibrillation. J Clin Pharmacol. 2023;63(4):383–96. https://doi.org/10.1002/jcph.2184.

Article  CAS  PubMed  Google Scholar 

Tun HN, Kyaw MT, Rafflenbeul E, Suástegui XL. Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis. Eur Cardiol. 2022;17:e11. https://doi.org/10.15420/ecr.2021.55. (Published 2022 May 13).

Article  PubMed  PubMed Central  Google Scholar 

Nederpelt CJ, Bijman Q, Krijnen P, Schipper IB. Equivalence of DOACS and LMWH for thromboprophylaxis after hip fracture surgery: systematic review and meta-analysis. Injury. 2022;53(3):1169–76. https://doi.org/10.1016/j.injury.2021.11.052.

Article  PubMed  Google Scholar 

Negm AM, Yamaura L, Clarke A, Chaudhry D, Cherppukaran T, Schneider P. Effectiveness of thromboprophylaxis agents following hip fracture: a systematic review and network meta-analysis. JB JS Open Access. 2023;8(4): e23.00064. https://doi.org/10.2106/JBJS.OA.23.00064.

Article  PubMed  PubMed Central  Google Scholar 

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2010;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561. (Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877).

Article  Google Scholar 

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638. (Epub 2011 Aug 10).

Article  CAS  PubMed  Google Scholar 

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039. (Epub 2011 Aug 27).

Article  CAS  PubMed  Google Scholar 

Reseptregisteret, FHI, https://www.reseptregisteret.no [search Nov 11th, 2020] (the Norwegian Prescription database, http://www.norpd.no).

European Medicines Agency (EMA), Eliquis, INN-apixaban. https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf.

Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clin Pharmacokinet. 2025;64(3):335–67. https://doi.org/10.1007/s40262-024-01466-0. (Epub 2025 Jan 11. Erratum in: Clin Pharmacokinet. 2025 Mar;64(3):463. 10.1007/s40262-025-01494-4).

Article  PubMed  PubMed Central  Google Scholar 

Merchant AA, Ling E. An approach to treating older adults with chronic kidney disease. CMAJ. 2023;195(17):E612–8. https://doi.org/10.1503/cmaj.221427.

Article  PubMed  PubMed Central  Google Scholar 

Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viktil KK, Lehre I, Ranhoff AH, Molden E. Serum concentrations and elimination rates of direct-acting oral anticoagulants (DOACs) in older hip fracture patients hospitalized for surgery: a pilot study. Drugs Aging. 2019;36(1):65–71. https://doi.org/10.1007/s40266-018-0609-4.

Article  CAS  PubMed  Google Scholar 

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H, External reviewers (2021). 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–76. https://doi.org/10.1093/europace/euab065. (Erratum in: Europace. 2021 Oct 9;23(10):1676. 10.1093/europace/euab157).

Article  PubMed  PubMed Central  Google Scholar 

Limcharoen S, Pongchaidecha M, Pimsi P, Limprasert S, Suphanklang J, Saelim W, Santimaleeworagun W, Boonmuang P. Do apixaban plasma levels relate to bleeding? The clinical outcomes and predictive factors for bleeding in patients with non-valvular atrial fibrillation. Biomedicines. 2022;10(8):2001. https://doi.org/10.3390/biomedicines10082001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizos T, Meid AD, Huppertz A, Dumschat C, Purrucker J, Foerster KI, Burhenne J, Czock D, Jenetzky E, Ringleb PA, Haefeli WE. Low exposure to direct oral anticoagulants is associated with ischemic stroke and its severity. J Stroke. 2022;24(1):88–97. https://doi.org/10.5853/jos.2020.04952. (Epub 2022 Jan 31).

Article  PubMed  PubMed Central  Google Scholar 

Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol. 2017;2(5):566–74. https://doi.org/10.1001/jamacardio.2017.0364.

Article  PubMed  Google Scholar 

Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med. 2003;70(4):361–71. https://doi.org/10.3949/ccjm.70.4.361.

Article  PubMed  Google Scholar 

Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proceedings (Baylor University. Medical Center). 2001;14(3), 305–306. https://doi.org/10.1080/08998280.2001.11927781.

Eidam A, Marji J, Benzinger P, Foerster KI, Burhenne J, Czock D, Stoll F, Blank A, Mikus G, Haefeli WE, Bauer JM. Frailty as a marker for the plasma concentrations of direct oral anticoagulants in older patients: results of an exploratory study. Drugs Aging. 2023;40(2):153–64. https://doi.org/10.1007/s40266-022-00999-y. (Epub 2023 Jan 13).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xun T, Lin Z, Wang X, Zhan X, Feng H, Gan D, Yang X. Advanced oxidation protein products downregulate CYP1A2 and CYP3A4 expression and activity via the NF-κB-mediated signaling pathway in vitro and in vivo. Lab Invest. 2021;101(9):1197–209. https://doi.org/10.1038/s41374-021-00610-9. (Epub 2021 May 24).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rege B, Krieg R, Gao N, Sarkar MA. Down-regulation of hepatic CYP3A in chronic renal insufficiency. Pharm Res. 2003;20(10):1600–6. https://doi.org/10.1023/a:1026135317578.

Article  CAS  PubMed  Google Scholar 

Egeland EJ, Witczak BJ, Zaré HK, Christensen H, Åsberg A, Robertsen I. Chronic inhibition of CYP3A is temporarily reduced by each hemodialysis session in patients with end-stage renal disease. Clin Pharmacol Ther. 2020;108(4):866–73. https://doi.org/10.1002/cpt.1875. (Epub 2020 Jun 1).

Article  CAS  PubMed  Google Scholar 

Hole K, Størset E, Olastuen A, Haslemo T, Kro GB, Midtvedt K, Åsberg A, Molden E. Recovery of CYP3A phenotype after kidney transplantation. Drug Metab Dispos. 2017;45(12):1260–5. https://doi.org/10.1124/dmd.117.078030. (Epub 2017 Sep 19).

Article  CAS  PubMed  Google Scholar 

Gupta S. P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging. 1995;7(1):19–29. https://doi.org/10.2165/00002512-199507010-00003.

Article  CAS  PubMed  Google Scholar 

Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood–brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79(6):540–8. https://doi.org/10.1016/j.clpt.2006.02.004.